Dr. Han on the Importance of pCR in Breast Cancer


In Partnership With:

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Heather ​S. Han, MD, medical oncologist and research director of Breast Oncology, Moffitt Cancer Center, discusses the importance of pathologic complete response (pCR) in breast cancer.

Patients with breast cancer who achieve a pCR following neoadjuvant therapy often have a better outcome compared with patients who do not, Han says. Moreover, pCR has been established as an important prognostic marker in breast cancer. 

Today, pCR continues to be used as a surrogate marker for patients with breast cancer ​following neoadjuvant therapy, explains Han.

Based on available data, the field can better determine the most optimal adjuvant treatment option for patients, Han concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
A panel of 4 experts on hematologic malignancies
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.